Other languages Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 15:24:19 06/05/2024 BST			5-day change	1st Jan Change
5,207 ^ILa	+1.19%		+5.55%	+36.49%

04-30	FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	MT
04-30	Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	05-01
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	04-30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	04-30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	04-30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	04-30
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	04-17
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	04-11
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	04-11
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	04-04
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	04-01
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	04-01
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics	04-01
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple	03-11
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing	03-07
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing	03-05
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing	03-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 09:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 08:19 pm